Participating Faculty: Improving the Quality of Life in Patients With Multiple Sclerosis

Improving the Quality of Life in Patients With Multiple Sclerosis: New Strategies and Opportunities

This supplement to The American Journal of Managed Care discusses unmet needs in improving quality of life in patients with MS. Also discussed is the management of specific MS symptoms, including fatigue, spasticity, and impaired mobility. Patients have reported that mobility impairment is one of the worst aspects of MS. Dalfampridine received FDA approval for all forms of MS specifically to improve walking; improved walking could potentially help contain some of the direct and indirect costs associated with MS care.

Faculty

Joseph R. Berger, MD

Ruth L. Works Professor and Chairman

Department of Neurology

University of Kentucky College of Medicine

Lexington, Kentucky

Augusto A. Miravalle, MD

Assistant Professor

Department of Neurology

University of Colorado School of Medicine

Aurora, Colorado

Jennifer Smrtka, MSN, ANP-BC, MSCN

Adult Nurse Practitioner

Fort Lauderdale Multiple Sclerosis Center

Pompano Beach, Florida

Howard L. Zwibel, MD

Founding Medical Director, Emeritus

Neuroscience Consultants

Comprehensive Multiple Sclerosis Center in affiliation with the National Multiple Sclerosis Center

Baptist Health Doctors Hospital Multiple Sclerosis Center

Coral Gables, Florida

Faculty Disclosures

These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

Joseph R. Berger, MD

Advisory board/consultant: Bayer, Biogen Idec, Eisai, Genentech, Millenium, Novartis, Perseid Therapeutics, Pfizer

Grants/honoraria: Bayer, Biogen Idec, EMD Serono

Augusto A. Miravalle, MD

Consultant: Advanced Studies in Medicine, Bayer, Biogen Idec, EMD Serono, Novartis, Questcor

Jennifer Smrtka, MSN, ANP-BC, MSCN

Board membership: International Organization of Multiple Sclerosis Nurses

Honoraria: Acorda Therapeutics, Inc, Bayer HealthCare, EMD Serono, Pfizer, Teva, Questcor, Novartis, PRIME, Consensus Medical, National Multiple Sclerosis Society, Multiple Sclerosis Association of America

Lectureship: Acorda Therapeutics, Inc

Howard L. Zwibel, MD

Advisory board/consultant: Acorda Therapeutics, Inc, Medscape, Teva Neuroscience

Honoraria: Acorda Therapeutics, Inc, Medscape, PRIME, Teva

Lectureship: Teva

This supplement was supported by Acorda Therapeutics, Inc.

Authors and subject matter contained in this supplement were determined by The American Journal of Managed Care publishing staff.

Publisher’s Note

The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of The American Journal of Managed Care. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Download PDF: Participating Faculty: Improving the Quality of Life in Patients With Multiple Sclerosis